Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

ClinicalTrials.gov ID: NCT00105508

Public ClinicalTrials.gov record NCT00105508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Study identification

NCT ID: NCT00105508
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: EMD Serono; Industry
Enrollment: 506 participants

Conditions and interventions

Conditions

Interventions

Placebo Drug
Sarizotan Drug

Drug

Eligibility (public fields only)

Age range: 30 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2004
Primary completion: Feb 27, 2006
Completion: Feb 27, 2006
Last update posted: Jul 25, 2018

2004 – 2006

United States locations

U.S. sites: 31
U.S. states: 21
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35233	—
Not listed	Huntsville	Alabama	35801	—
Not listed	La Jolla	California	92037	—
Not listed	Oxnard	California	93030	—
Not listed	Sacramento	California	95817	—
Not listed	Englewood	Colorado	80113	—
Not listed	Danbury	Connecticut	06810	—
Not listed	Farmington	Connecticut	06030-1840	—
Not listed	Jacksonville	Florida	32209	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Maitland	Florida	32751	—
Not listed	St. Petersburg	Florida	33703	—
Not listed	Decatur	Georgia	30033	—
Not listed	Chicago	Illinois	60611-3078	—
Not listed	Springfield	Illinois	62702	—
Not listed	Des Moines	Iowa	50309	—
Not listed	New Orleans	Louisiana	70112	—
Not listed	Scarborough	Maine	04074	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Southfield	Michigan	48034	—
Not listed	Edison	New Jersey	08818	—
Not listed	New Hyde Park	New York	11040	—
Not listed	New Hyde Park	New York	12401	—
Not listed	New York	New York	10016	—
Not listed	Durham	North Carolina	27705	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Brentwood	Tennessee	37027	—
Not listed	South Ogden	Utah	84403	—
Not listed	Spokane	Washington	99204	—
Not listed	Milwaukee	Wisconsin	53233	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00105508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2018 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00105508 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →